Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments
Authors:
- 1 July 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer
- Vol. 38 (11) , 1501-1511
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration?American Journal of Ophthalmology, 1999
- Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-?-2a in patients with metastatic melanomaCancer, 1999
- Dacarbazine–vindesine versus dacarbazine–vindesine–cisplatin in disseminated malignant melanoma. A randomised phase III trialEuropean Journal of Cancer, 1998
- Immunotherapy of metastatic melanoma with interferon-α and interleukin-2: Pattern of progression in responders and patients with stable disease with or without resection of residual lesionsEuropean Journal of Cancer, 1994
- Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysisCancer, 1993
- Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trialsCancer, 1993
- A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanomaCancer, 1993
- Treatment of Metastatic Malignant Melanoma with Dacarbazine plus TamoxifenNew England Journal of Medicine, 1992
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: A southwest oncology group studyMedical and Pediatric Oncology, 1982